Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURF-301: TYRA-300 in advanced urothelial carcinoma and other FGFR3-altered solid tumors
2023-507589-22-00Phase 2Completed
- Sponsor
- Tyra Biosciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of dabogratinib in transitional cell carcinoma (TCC) and Nonhematologic neoplasms (3 arms), sponsored by Tyra Biosciences. Primary endpoints: Dose-limiting toxicities and Objective response rate. Started May 2024; status: completed.
02
Drugs
dabogratinib
03
Conditions
transitional cell carcinoma (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-507589-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507589-22-00.